
A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for human transplantation. . . . → Read More: Gene-Edited Transplant Organ Company Raises $125M
|
|||||
![]() A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for human transplantation. . . . → Read More: Gene-Edited Transplant Organ Company Raises $125M ![]() A start-up company, spun off from a biomedical engineering lab at MIT, is raising $80 million for therapies made from synthetic circular RNA. . . . → Read More: Synthetic RNA Start-Up Gains $80M in Early Funds ![]() A developer of therapies using highly precise gene editing is acquiring a company delivering gene therapies identified with DNA bar codes. . . . → Read More: Gene-Editing Biotech Acquires DNA Bar Code Company ![]() CB Insights compiled a list of the top technology venture investors in each state and D.C., and displayed the investors on a map. . . . → Read More: Infographic – Top Venture Investor in Each State ![]() Three new funds are financing start-up companies creating solutions for health issues in less-developed countries and early-stage life science businesses. . . . → Read More: New Funds Backing Global Health, Early-Stage Ventures ![]() A new enterprise using artificial intelligence to analyze individual cells for immune-related diagnostics and therapies is raising $6 million in seed funds. . . . → Read More: AI Cell Analysis Start-Up Raises $6M Seed Funds ![]() Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies. . . . → Read More: AbbVie Licenses Engineered Crispr Cell Process ![]() A new $300 million venture capital fund is underway that aims to support technology start-ups often left behind by larger mainstream investors. . . . → Read More: New Venture Fund Backs Underserved, Academic Start-Ups ![]() A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO ![]() A developer of treatments for rare neurological diseases derived from cannabis is being acquired by Jazz Pharmaceuticals in a $7.2 billion deal. . . . → Read More: Cannabidiol Drug Maker Acquired in $7.2B Deal |
|||||
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |